← back to search

Ariel M. Rubinstein

Hebrew University of Jerusalem · IL
Area of research
Cell Biology · Molecular Biology
Research interest
Research interests include Medicine, Heparanase, Cancer research, Cancer, Breast cancer, and Inflammation.
h-index
citations
722
works
16
NIH funding
primary concept
email

Recent publications

Effective head and neck cancer treatment combines radiation and local extended cisplatin release
Journal of Controlled Release 2025cited by 3position: middledoi
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer
Molecular Cancer 2024cited by 12position: middledoi
Radiation-Induced Nephropathy in the Murine Model Is Ameliorated by Targeting Heparanase
Biomedicines 2023cited by 3position: middledoi
Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
Theranostics 2022cited by 24position: middledoi
Computational quantification and characterization of independently evolving cellular subpopulations within tumors is critical to inhibit anti-cancer therapy resistance
Genome Medicine 2022cited by 18position: middledoi
Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma
Cells 2022cited by 13position: middledoi
Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations
npj Precision Oncology 2021cited by 29position: middledoi
Drug-Induced Resistance and Phenotypic Switch in Triple-Negative Breast Cancer Can Be Controlled via Resolution and Targeting of Individualized Signaling Signatures
Cancers 2021cited by 28position: middledoi
Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer
npj Breast Cancer 2021cited by 20position: middledoi
Dissecting the role of crosstalk between glioblastoma subpopulations in tumor cell spreading
Oncogenesis 2020cited by 16position: middledoi
Dichotomic role of heparanase in a murine model of metabolic syndrome
Cellular and Molecular Life Sciences 2020cited by 5position: middledoi
p53 elevation in human cells halt SV40 infection by inhibiting T-ag expression
Oncotarget 2016cited by 14position: middledoi
Periodontal pathogens <i>Porphyromonas gingivalis</i> and <i>Fusobacterium nucleatum</i> promote tumor progression in an oral-specific chemical carcinogenesis model
Oncotarget 2015cited by 408position: middledoi
Role of Heparanase-Driven Inflammatory Cascade in Pathogenesis of Diabetic Nephropathy
Diabetes 2014cited by 88position: middledoi
Induction of heparanase by <scp>HPV</scp> E6 oncogene in head and neck squamous cell carcinoma
Journal of Cellular and Molecular Medicine 2013cited by 21position: middledoi
Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice
Cellular and Molecular Life Sciences 2013cited by 20position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Elkin · Hebrew University of Jerusalem8 papers (2013–2023)Nataly Kravchenko‐Balasha · Hebrew University of Jerusalem8 papers (2020–2025)Amichay Meirovitz · Soroka Medical Center7 papers (2013–2023)Esther Hermano · Hebrew University of Jerusalem6 papers (2013–2023)Heba Alkhatib · Hebrew University of Jerusalem4 papers (2021–2024)Swetha Vasudevan · Hebrew University of Jerusalem4 papers (2021–2022)Sangita Roy Chowdhury · Hebrew University of Jerusalem4 papers (2021–2024)Israël Vlodavsky · Technion – Israel Institute of Technology3 papers (2013–2022)Shira Stefansky · Hebrew University of Jerusalem3 papers (2021–2022)Efrat Flashner-Abramson · Hebrew University of Jerusalem3 papers (2021–2022)Ibukun Adesoji Adejumobi · Hebrew University of Jerusalem3 papers (2020–2021)Amir Sonnenblick · Ariel University3 papers (2021–2024)Shay Sharon · Hebrew University of Jerusalem2 papers (2022–2025)Maria R. Jubran · Hebrew University of Jerusalem2 papers (2020–2022)Avital Granit · Hebrew University of Jerusalem2 papers (2022–2024)Kim Sheva · Hebrew University of Jerusalem2 papers (2022–2023)Daniela Vilenski · Hebrew University of Jerusalem2 papers (2021–2022)Tamar Peretz-Yablonsky · Hebrew University of Jerusalem2 papers (2022–2024)Jin‐Ping Li · The First Affiliated Hospital, Sun Yat-sen University2 papers (2014–2020) · 2 papers (2020–2023)